KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) (2020 - 2025)
KalVista Pharmaceuticals recorded quarterly EPS (Weighted Average and Diluted) of -$1.12 in Q3 2025, down 13.13% quarter-over-quarter from -$0.99 in Q2 2025, and down 28.74% year-over-year from -$1.57 in Q3 2024.
KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$1.12 for Q3 2025.
- In Q3 2025, EPS (Weighted Average and Diluted) fell 28.74% year-over-year to -$1.12; the TTM figure through Jul 2025 stood at -$3.89 (down 8.66% YoY), while the FY2025 annual figure was -$3.69, down 7.27% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$1.12 for Q3 2025 at KalVista Pharmaceuticals, down from -$0.99 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.66 in Q3 2021 to a low of -$1.12 in Q3 2025.
- A 5-year average of -$0.88 and a median of -$0.9 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) tumbled 91.74% in 2021 and climbed 23.47% in 2023, its largest moves.
- KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.8 in 2021, then slipped by 12.5% to -$0.9 in 2022, then gained by 11.11% to -$0.8 in 2023, then dropped by 13.75% to -$0.91 in 2024, then dropped by 23.08% to -$1.12 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$1.12, -$0.99, and -$0.91 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -1.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -1.12 |
| Apr 30, 2025 | -0.99 |
| Oct 31, 2024 | -0.91 |
| Jul 31, 2024 | -0.87 |
| Apr 30, 2024 | -1.07 |
| Jan 31, 2024 | -0.84 |
| Oct 31, 2023 | -0.80 |
| Jul 31, 2023 | -0.74 |
| Apr 30, 2023 | -0.75 |
| Jan 31, 2023 | -0.75 |
| Oct 31, 2022 | -0.90 |
| Jul 31, 2022 | -0.94 |
| Apr 30, 2022 | -0.98 |
| Jan 31, 2022 | -0.92 |
| Oct 31, 2021 | -0.80 |
| Jul 31, 2021 | -0.66 |
| Apr 30, 2021 | -0.93 |
| Apr 30, 2020 | -0.48 |